Wall Street brokerages expect Inogen (NASDAQ:INGN) to post sales of $62.60 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Inogen’s earnings, with estimates ranging from $60.89 million to $64.80 million. Inogen posted sales of $52.50 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 19.2%. The company is scheduled to report its next earnings report after the market closes on Tuesday, May 8th.
According to Zacks, analysts expect that Inogen will report full-year sales of $303.29 million for the current financial year, with estimates ranging from $303.00 million to $303.58 million. For the next fiscal year, analysts anticipate that the firm will report sales of $358.58 million per share, with estimates ranging from $350.54 million to $363.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Inogen.
Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. Inogen had a return on equity of 13.47% and a net margin of 8.42%. The company had revenue of $63.79 million during the quarter, compared to analyst estimates of $62.01 million.
In other Inogen news, Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction on Tuesday, April 17th. The stock was sold at an average price of $139.82, for a total value of $139,820.00. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $139,820. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction on Monday, April 16th. The stock was sold at an average price of $139.79, for a total value of $349,475.00. Following the completion of the sale, the executive vice president now directly owns 8,374 shares of the company’s stock, valued at approximately $1,170,601.46. The disclosure for this sale can be found here. In the last three months, insiders sold 115,718 shares of company stock valued at $14,059,611. Corporate insiders own 5.29% of the company’s stock.
Several institutional investors have recently bought and sold shares of INGN. Lenox Wealth Advisors Inc. bought a new stake in shares of Inogen in the 4th quarter worth $100,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Inogen by 1,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after acquiring an additional 1,000 shares during the period. Simplex Trading LLC bought a new stake in shares of Inogen in the fourth quarter worth $153,000. LS Investment Advisors LLC grew its holdings in shares of Inogen by 138.6% in the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after acquiring an additional 880 shares during the period. Finally, Everence Capital Management Inc. bought a new stake in shares of Inogen in the fourth quarter worth $208,000. 98.97% of the stock is owned by institutional investors and hedge funds.
INGN stock traded down $0.15 on Tuesday, reaching $141.08. 65,575 shares of the company traded hands, compared to its average volume of 138,444. Inogen has a one year low of $78.30 and a one year high of $144.05. The firm has a market cap of $2,992.87, a PE ratio of 107.69, a price-to-earnings-growth ratio of 3.93 and a beta of 1.03.
ILLEGAL ACTIVITY NOTICE: “Inogen (INGN) Expected to Post Quarterly Sales of $62.60 Million” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3380326/inogen-ingn-expected-to-post-quarterly-sales-of-62-60-million-2.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.